

**STERLING BIOTECH LIMITED**

Regd. Office: 43, Atlanta Building, Nariman Point, Mumbai - 400 021

**UNAUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THE THIRD QUARTER ENDED 30 SEPTEMBER 2012**

**PART I**

(Rs. in Lacs)

Sr. No.	Particulars	Three Months ended			Nine Months ended		Twelve Months ended
		30/09/2012	30/06/2012	30/09/2011	30/09/2012	30/09/2011	31/12/2011
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	<b>Income from Operations</b>						
	a) Net Sales/Income from Operations	19,802.42	22,567.82	45,104.29	63,122.59	133,537.61	166,195.39
	b) Other Operating Income	203.21	213.45	226.38	645.56	746.44	930.78
	<b>c) Total Income from Operations</b>	<b>20,005.63</b>	<b>22,781.27</b>	<b>45,330.67</b>	<b>63,768.15</b>	<b>134,284.05</b>	<b>167,126.17</b>
2	<b>Expenses</b>						
	a) Cost of materials consumed	12,086.87	11,920.90	25,022.59	42,234.94	67,661.93	102,799.60
	b) Purchase of stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	412.42	4,249.10	1,258.41	1,730.88	(3,843.51)	(14,836.69)
	d) Employee benefits expense	1,339.62	1,342.76	1,327.73	4,040.20	3,723.69	5,056.56
	e) Depreciation and amortization expense	6,535.65	6,321.16	6,265.27	19,219.25	19,296.83	25,709.95
	f) Other Expenses	1,352.21	1,321.71	2,671.39	3,906.65	12,538.70	9,435.24
	<b>g) Total Expenses</b>	<b>21,726.77</b>	<b>25,155.63</b>	<b>36,545.39</b>	<b>71,131.92</b>	<b>99,377.64</b>	<b>128,164.66</b>
3	<b>Profit / (Loss) from Operations before Other Income and finance Costs (1-2)</b>	<b>(1,721.14)</b>	<b>(2,374.36)</b>	<b>8,785.28</b>	<b>(7,363.77)</b>	<b>34,906.41</b>	<b>38,961.51</b>
4	Other Income	0.00	0.00	0.00	0.00	0.00	0.00
5	<b>Profit / (Loss) from Ordinary activities before finance costs (3+4)</b>	<b>(1,721.14)</b>	<b>(2,374.36)</b>	<b>8,785.28</b>	<b>(7,363.77)</b>	<b>34,906.41</b>	<b>38,961.51</b>
6	Finance Costs	9,629.04	10,932.67	7,184.38	30,932.94	19,775.96	27,043.08
7	<b>Profit / (Loss) from Ordinary Activities after finance costs but before tax (5-6)</b>	<b>(11,350.18)</b>	<b>(13,307.03)</b>	<b>1,600.90</b>	<b>(38,296.71)</b>	<b>15,130.45</b>	<b>11,918.43</b>
8	Tax expense						
	a) Current	0.00	0.00	320.18	0.00	2,815.85	570.02
	b) Deferred	(3,683.00)	(4,317.00)	208.12	(12,425.00)	1,916.30	300.01
	c) Total	(3,683.00)	(4,317.00)	528.30	(12,425.00)	4,732.15	870.03
9	<b>Net Profit / (Loss) from Ordinary Activities after tax (7-8)</b>	<b>(7,667.18)</b>	<b>(8,990.03)</b>	<b>1,072.60</b>	<b>(25,871.71)</b>	<b>10,398.30</b>	<b>11,048.40</b>
10	Extraordinary Items	0.00	0.00	0.00	0.00	(1,061.94)	(9,135.22)
11	<b>Net Profit / (Loss) for the period (9+10)</b>	<b>(7,667.18)</b>	<b>(8,990.03)</b>	<b>1,072.60</b>	<b>(25,871.71)</b>	<b>9,336.36</b>	<b>1,913.18</b>
12	Prior year adjustment	0.00	0.00	0.00	0.00	0.00	81.69
13	<b>Profit available for appropriation</b>	<b>(7,667.18)</b>	<b>(8,990.03)</b>	<b>1,072.60</b>	<b>(25,871.71)</b>	<b>9,336.36</b>	<b>1,994.87</b>
14	Paid-up equity share capital (Face Value of Re.1/- per share)	2,678.74	2,678.74	2,678.74	2,678.74	2,678.74	2,678.74
15	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year						246,410.14
16.i	Earnings Per Share (EPS) (before extraordinary items) (F.V. of Re.1/- each) (not annualised)						
	a) Basic	(2.86)	(3.36)	0.40	(9.66)	3.88	4.12
	b) Diluted	(2.53)	(2.97)	0.35	(8.55)	3.49	3.65
16.ii	Earnings Per Share (EPS) (after extraordinary items) (F.V. of Re.1/- each) (not annualised)						
	a) Basic	(2.86)	(3.36)	0.40	(9.66)	3.44	0.71
	b) Diluted	(2.53)	(2.97)	0.35	(8.55)	3.09	0.63

**STERLING BIOTECH LIMITED**  
Regd. Office: 43, Atlanta Building, Nariman Point, Mumbai - 400 021

Select Information for the Quarter ended 30 September 2012

**PART II**

Sr. No.	Particulars	Three Months ended			Nine Months ended		Twelve Months ended
		30/09/2012	30/06/2012	30/09/2011	30/09/2012	30/09/2011	31/12/2011
<b>A</b>	<b>PARTICULARS OF SHAREHOLDING</b>						
1	Public Shareholding						
	- Number of shares	131,861,090	131,861,090	133,240,656	131,861,090	133,240,656	131,861,090
	- Percentage of shareholding	49.23%	49.23%	49.74%	49.23%	49.74%	49.23%
2	Promoters and Promoter Group Shareholding						
	a) Pledged/Encumbered						
	Number of shares	50,816,835	50,816,835	75,777,817	50,816,835	75,777,817	50,816,835
	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	55.94%	55.94%	84.71%	55.94%	84.71%	55.94%
	Percentage of shares (as a % of the total share capital of the Company)	18.97%	18.97%	28.29%	18.97%	28.29%	18.97%
	b) Non-encumbered						
	Number of shares	40,023,300	40,023,300	13,682,752	40,023,300	13,682,752	40,023,300
	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	44.06%	44.06%	15.29%	44.06%	15.29%	44.06%
	Percentage of shares (as a % of the total share capital of the Company)	14.94%	14.94%	5.11%	14.94%	5.11%	14.94%

Sr. No.	Particulars	Quarter ended 30/09/2012
<b>B</b>	<b>INVESTOR COMPLAINTS</b>	
	Pending at the beginning of the Quarter	0
	Received during the quarter	24
	Disposed of during the quarter	24
	Remaining unresolved at the end of the quarter	0

**Notes:**

- 1 The company's operations fall under single segment hence segment reporting as defined in Accounting Standard 17 is not applicable.
- 2 The above Financial results have been reviewed by the Audit Committee and taken on record by the Board of Directors in its meeting held on 09 November 2012.
- 3 The Statutory Auditors have carried out a limited review of the financial results for the quarter ended 30 September 2012
- 4 The Company has Overseas Subsidiary and there are no business operations in the subsidiary company.
- 5 Previous period figures have been regrouped/reclassified, wherever necessary.

**For and on Behalf of  
STERLING BIOTECH LIMITED**

Place : Mumbai  
Date : 09 November 2012.

**Chetan J. Sandesara  
Joint Managing Director**